To understand the role that TAMs play in the efficacy of the poly(ADP)ribosylation inhibitor (PARPi) olaparib in an immune-competent host, we treated a cohort of tumor-bearing mice with and without ablation of TAMs. This evidence concerns the gene WDTC1 and neoplasm.